Entropy Technologies LP Boosts Position in Dynavax Technologies Corporation (NASDAQ:DVAX)

Key Points

• Entropy Technologies LP increased its ownership in Dynavax Technologies by 111.5% during the first quarter, acquiring over 54,000 additional shares, bringing its total shares to 102,834.
• Dynavax Technologies reported an earnings per share (EPS) of $0.14 for the last quarter, exceeding estimates of $0.12, with revenue of $95.44 million compared to anticipated revenue of $87.55 million.
• Analysts have mixed ratings for Dynavax, with one report upgrading it to a "buy" while another lowered the target price to $10, resulting in an average rating of "Moderate Buy" with a consensus target of $24.33.

Entropy Technologies LP lifted its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 111.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 102,834 shares of the biopharmaceutical company's stock after purchasing an additional 54,213 shares during the quarter. Entropy Technologies LP owned about 0.09% of Dynavax Technologies worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Deep Track Capital LP boosted its holdings in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock valued at $227,197,000 after acquiring an additional 5,265,000 shares during the period. Deerfield Management Company L.P. Series C boosted its holdings in Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock valued at $66,325,000 after acquiring an additional 5,172,263 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Dynavax Technologies by 4.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock valued at $51,948,000 after acquiring an additional 171,933 shares during the period. Blair William & Co. IL boosted its holdings in Dynavax Technologies by 0.5% during the 1st quarter. Blair William & Co. IL now owns 2,272,707 shares of the biopharmaceutical company's stock valued at $29,477,000 after acquiring an additional 11,030 shares during the period. Finally, Invesco Ltd. boosted its holdings in Dynavax Technologies by 33.8% during the 1st quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company's stock valued at $28,633,000 after acquiring an additional 558,046 shares during the period. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DVAX has been the subject of a number of research analyst reports. The Goldman Sachs Group lowered their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a report on Thursday, April 17th. Wall Street Zen upgraded Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Finally, JMP Securities lifted their price objective on Dynavax Technologies from $31.00 to $32.00 and gave the company a "market outperform" rating in a research note on Friday, August 8th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $24.33.

Dynavax Technologies Stock Down 1.8%

Shares of DVAX traded down $0.20 during midday trading on Thursday, hitting $10.62. The company had a trading volume of 1,051,552 shares, compared to its average volume of 2,097,407. The company's 50-day simple moving average is $10.54 and its 200-day simple moving average is $11.52. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The firm has a market capitalization of $1.25 billion, a P/E ratio of -23.09 and a beta of 1.09. Dynavax Technologies Corporation has a 1 year low of $9.22 and a 1 year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.02. The firm had revenue of $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. Dynavax Technologies had a positive return on equity of 5.10% and a negative net margin of 16.67%. As a group, sell-side analysts expect that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.